ClinicalTrials.gg
RecruitingNCT07600580Updated Jun 16, 2026

The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response

A Phase 4 interventional study of bilateral ultrasound guided intermediate cervical plexus block with 0,25% levobupivacaine in Thyroid Cancer, Thyroid and Parathyroid Surgery and Hyperthyreosis and Goiter, sponsored by University Hospital Dubrava. Recruiting at 1 site in Croatia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University Hospital Dubrava · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled May 2024, registered May 2026).
  • Started May 2024; still recruiting 2 years 5 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to determine the impact of ultrasound-guided bilateral intermediate cervical plexus block on the surgical stress response in patients undergoing total thyroidectomy, as measured by the concentration of stress and inflammatory biomarkers in the participants' saliva and serum.

The study will be conducted on 48 subjects divided into two groups of 24: a control group receiving total intravenous anesthesia (TIVA) and an experimental group receiving TIVA combined with a bilateral intermediate cervical plexus block.

Investigators hypothesized that a combination of bilateral intermediate cervical plexus block and total intravenous anesthesia (TIVA) would reduce the surgical stress response, as measured by salivary and blood biomarkers, compared to TIVA alone in patients undergoing total thyroidectomy.

Should the research confirm the hypothesis, it will provide an objective scientific argument for including the block in standard anesthetic protocols for total thyroidectomy surgeries, with the ultimate goal of reducing the surgical stress response and ensuring faster patient recovery.

Read the detailed description

The study will be conducted at the Dubrava University Hospital, within the Department of Anesthesiology, Resuscitation, and Intensive Care Medicine and the Department of Otorhinolaryngology and Head and Neck Surgery. The sample will consist of 48 patients scheduled for total thyroidectomy, divided into two groups of 24 subjects each:

Group C (Control): total intravenous anesthesia (TIVA) Group E (Experimental): TIVA + bilateral intermediate cervical plexus block with 0.25% levobupivacaine

The study will include patients of both sexes, aged 18 and older, with euthyroid status, classified as ASA I and ASA II, for whom total thyroidectomy is indicated and who have signed an informed consent form to participate in the study.

Exclusion criteria include patients who refuse to sign the informed consent, patients with an infection at the block injection site, hypersensitivity or contraindications to the drugs used in the study, presence of hypothyroidism or hyperthyroidism at the time of surgery, presence of substernal goiter, or additional surgical interventions during the procedure. Furthermore, patients with prior neck surgery or radiation, coagulopathy, uncontrolled respiratory disease, diabetes mellitus, autoimmune disease, patients on chronic corticosteroid therapy, smokers and pregnant women will be excluded.

The study is single-blinded; participants will only learn which group they were assigned to after the completion of the postoperative follow-up period.

The efficacy of the investigated protocols and their comparison will be assessed by laboratory determination of surgical stress response biomarkers in the participants' saliva and serum.

STUDY PLAN Participant randomization into the control or experimental group will be performed using a computer-generated list of random numbers with a 1:1 allocation ratio. The assignment sequence will be predetermined and sealed in numbered envelopes, which will be opened immediately before the induction of anesthesia.

Due to the circadian rhythm of cortisol and alpha-amylase, all study participants will undergo surgery at comparable times of day.Thirty minutes before the start of surgery, venous blood samples will be collected to determine baseline concentrations of cortisol, IL-6, CRP, glucose, alpha-amylase activity and total white blood cell count. Simultaneously, a non-stimulated saliva sample will be collected using a salivette to determine salivary concentrations of cortisol, IL-6, and alpha-amylase activity.

Premedication with midazolam (5 mg i.m.) will be administered on the ward 20 minutes before the surgical procedure.

For the induction of general anesthesia, sufentanil (0.15 mcg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used. Following endotracheal intubation, general anesthesia will be maintained with a continuous infusion of propofol. Anesthesia depth will be monitored using the Bispectral Index (BIS), with the propofol dose titrated to maintain BIS values between 40 and 60. Neuromuscular relaxation will be maintained by intermittent administration of 10 mg rocuronium every 30 minutes. After induction, 0.2 mg/kg of intravenous dexamethasone will be administered for anti-edematous prophylaxis. The dexamethasone dose is standardized in both groups, and its influence on inflammatory markers will be accounted for during data interpretation.

Following the induction of general anesthesia, the experimental group will receive a bilateral intermediate cervical plexus block Systolic, diastolic, and mean arterial pressure, heart rate, and SpO2 will be recorded upon entry into the operating room, after induction, after the surgical incision, and every 15 minutes during surgery as parameters of the hemodynamic response to surgical stress. End-tidal CO2 (EtCO2) and BIS values will also be recorded at 15-minute intervals after induction. In the event of an increase in heart rate or mean arterial pressure of 20% or more from baseline, a bolus of 0.1 mcg/kg sufentanil will be administered. During wound closure, 1 g of intravenous paracetamol will be administered. At the end of the surgery, reversal of neuromuscular blockade will be performed with sugammadex at a dose of 2 mg/kg.

After emergence, block success will be confirmed by the absence of pain during a pinprick test in the anesthetized area of the neck.

Postoperatively, heart rate, systolic, diastolic, and mean arterial pressure, SpO2 and respiratory rate will be recorded at 15 minutes, 30 minutes, and 1, 4, 12, and 24 hours after surgery. At the same time points, postoperative pain levels will be assessed using a Visual Analog Scale (VAS) from 0 to 10 at rest and during swallowing. For pain scores of VAS >4 , 100 mg of intravenous ketoprofen will be administered. If pain persists, an additional 1 mg/kg of tramadol will be given. The analgesic protocol is standardized for both groups. Total analgesic consumption during the first 24 hours and the time to first analgesic request will be recorded.

The degree of postoperative sedation will be assessed using the Richmond Agitation-Sedation Scale (RASS) at 15 minutes, 30 minutes, 1, and 4 hours postoperatively.

Saliva samples for cortisol, IL-6, and alpha-amylase will be collected 1 and 24 hours after surgery.

Venous blood samples for cortisol, IL-6, alpha-amylase, CRP, glucose, and total white blood cell count will be taken at 1, 24, and 48 hours postoperatively.

STATISTICAL ANALYSIS Based on previous research, to detect differences between the two groups with an effect size f = 0.40, a power of 0.80, and a significance level of 0.05, the minimum required sample size is 48 participants (24 per group). Categorical data will be presented as absolute and relative frequencies. Differences in categorical variables will be tested using the Chi-square test or, where appropriate, Fisher's exact test. Changes in categorical variables between measurements will be analyzed using the McNemar-Bowker test and the Marginal Homogeneity test.The normality of distribution for numerical variables will be assessed using the Shapiro-Wilk test. Continuous data will be described by the mean and standard deviation for normally distributed data; otherwise, data will be presented as the median and interquartile range (IQR).Differences in continuous variables between the control and experimental groups will be tested using the Student's t-test or the Mann-Whitney U test, depending on the normality of the distribution (with the reported difference and its associated 95% confidence interval).Differences in continuous variables between two time points will be tested using the paired t-test or the Wilcoxon signed-rank test (with the reported difference and 95% CI), depending on the distribution. For comparisons across more than two time points, repeated measures ANOVA or the Friedman test (with post hoc Conover test) will be used.The correlation between normally distributed continuous variables will be assessed using the Pearson correlation coefficient, while the Spearman correlation coefficient will be used for non-normally distributed data.All p-values will be two-sided. The level of significance will be set at alpha = 0.05.

The expected contribution of this research is based on evaluating the impact of bilateral intermediate cervical plexus block on the modulation of the surgical stress response during total thyroidectomy and the postoperative period. The study aims to determine whether the application of this method is associated with lower consumption of opioid and non-opioid analgesics and a more stable cardiovascular profile in patients. These results could provide a scientific foundation for integrating this regional technique into standard multimodal analgesia protocols, with the goal of optimizing perioperative care.

02

Conditions studied

  • Thyroid Cancer
  • Thyroid and Parathyroid Surgery
  • Hyperthyreosis and Goiter
  • Surgical Stress Response

Keywords

  • bilateral intermediate cervical plexus block
  • surgical stress response
  • IL-6, cortisol, alpha-amylase
  • saliva analysis
03

In context

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

This study's planned enrollment of 48 is close to the median of 53 across 520 interventional studies indexed under Thyroid Neoplasms.

Browse Thyroid Neoplasms studies →

Lead sponsor

University Hospital Dubrava is the lead sponsor of 43 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patienets of both sexes
  • 18 years of age and older
  • or ASA II
  • euthyroid status
  • signed

Exclusion criteria

Exclusion Criteria:

  • patients who refuse to sign the form
  • infection at the block injection site
  • or to the medications used in the study
  • hypothyroidism or hyperthyroidism at the time of surgery
  • presence of substernal goiter
  • additional surgical interventions during the procedure
  • history of previous neck surgery or radiation
  • coagulopathy
  • uncontrolled respiratory disease
  • diabetes mellitus
  • disease
  • chronic therapy
  • smokers
  • pregnant women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
48 participants (estimated)

Study arms

  • No intervention
    total intravenous anesthesia (TIVA)
  • Experimental
    TIVA + bilateral intermediate cervical plexus block with 0.25% levobupivacaine

    Other: bilateral ultrasound guided intermediate cervical plexus block with 0,25% levobupivacaine

Interventions

  • Otherbilateral ultrasound guided intermediate cervical plexus block with 0,25% levobupivacaine

    Following the induction of general anesthesia in the study group, a bilateral intermediate cervical plexus block will be performed. The subject's head is carefully turned away from the side of the neck where the block is being administered. A linear ultrasound probe is placed transversely at the midpoint of an imaginary line connecting the mastoid process and the sternal attachment of the sternocleidomastoid muscle (SCM). The cervical plexus is visualized as a small cluster of hypoechoic nodules beneath the posterolateral border of the SCM and immediately above the prevertebral fascia. After sterile preparation, a 22-gauge needle is inserted under ultrasound guidance in a lateromedial direction. The needle tip is positioned within the specified space, approximately 2 cm medial to the skin entry point. Following a negative aspiration test, 10 mL of 0.25% levobupivacaine is injected and visualized on the ultrasound screen. The same procedure is then repeated on the contralateral side.

06

What researchers measure

Primary outcomes

  1. Serum Cortisol Concentration

    Assessment of serum cortisol concentration as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: nmol/L

    Time frame: Preoperative baseline, 1 hour postoperative, 24 hours postoperative and 48 hours postoperative

  2. Salivary Cortisol Concentration

    Assessment of salivary cortisol concentration as a biomarker of surgical stress response. Unit of measure: nmol/L

    Time frame: Preoperative baseline, 1 hour and 24 hour postoperative

  3. Serum IL-6 Concentration

    Assessment of serum IL-6 concentration as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: pg/mL

    Time frame: Preoperative baseline, 1 hour, 24 hours and 48 hours postoperative

  4. Salivary IL-6 Concentration

    Assessment of salivary IL-6 concentration as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: pg/mL

    Time frame: Preoperative baseline, 1 hour and 24 hours postoperative

  5. Serum Alpha-amylase Activity

    Assessment of serum alpha-amylase activity as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: U/L

    Time frame: Preoperative baseline, 1 hour, 24 hours and 48 hours postoperative

  6. Salivary Alpha-amylase Activity

    Assessment of salivary alpha-amylase activity as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: U/L

    Time frame: Preoperative baseline, 1 hour and 24 hours postoperative

  7. Serum CRP Concentration

    Assessment of serum cortisol concentration as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: mg/L

    Time frame: Preoperative baseline, 1 hour, 24 hours and 48 hours postoperative

  8. Serum Glucose Concentration

    Assessment of serum glucose concentration as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: mmol/L

    Time frame: Preoperative baseline, 1 hour, 24 hours and 48 hours postoperative

  9. Total Lukocyte Count

    Assessment of total leukocyte count as a biomarker of surgical stress response in patents undergoing total thyroidectomy with or without intermediate cervical plexus block combined with total intravenous anesthesia. Unit of measure: x10\*9/L

    Time frame: Preoperative baseline, 1 hour, 24 hours and 48 hours postoperative

Secondary outcomes

  1. Total Intraoperative Sufentanyl consumption

    assessment of total sufentanyl consumption during surgery. Unit of measure: mcg/kg/min

    Time frame: Intraoperative period

  2. Total Postoperative Analgetics Consumption

    Assessment of total ketoprofen and tramadol consumption during the postoperative period. Unit of measure: mg

    Time frame: First 24 hours postoperative

  3. Time to First Rescue Analgesia

    Assessment of the time elapsed from the end of surgery until the first request for rescue analgesia. Unite of measure: minutes

    Time frame: First 24 hours postoperative

  4. Postoperative Pain Intensity

    Assessment of postoperative pain intensity using the visual analogue pain scale where 0 indicates no pain and 10 indicates worst possible pain. Unit of measure: 0-10

    Time frame: 15 and 30 minutes, 1,4,12,48 hours postoperative

  5. Hemodynamic Stability

    Assessment of intraoperative and postoperative hemodynamic stability including heart rate, systolic and diastolic blood pressure and mean arterial pressure. Unit of measure: beats/minute, mmHg

    Time frame: Intraoperative period and first 48 hours postoperative

  6. Postoperative Sedation Level

    Assessment of postoperative sedation level using Richmond Agitation-Sedation Scale. Unit of measure -5 to +4

    Time frame: 15 minutes, 30 minutes, 1 hour and 4 hours postoperative

  7. Postoperative Nausea and Vomiting (PONV)

    Assessment of the incidence of PONV following surgery. Unit of measure: number of participants with nausea and/or vomiting episodes

    Time frame: First 24 hours postoperative

Other outcomes

  1. The incidence of complication of the block

    Time frame: From application of the block to 48 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 20, 2026
StartActual
May 13, 2024
Primary completionEst.
Feb 3, 2027
CompletionEst.
Aug 1, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600580
Lead sponsor
University Hospital Dubrava
Responsible party
Antonija Mihelcic (Anesthesiologist, MD, University Hospital Dubrava) — Principal investigator
First posted
May 20, 2026
Start date
May 13, 2024
Primary completion
Feb 3, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Antonija Mihelčić
Contact
antonijamihelcic@yahoo.com
+385996830715

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion